Literature DB >> 18832960

A review of second-generation antipsychotic discontinuation in first-episode psychosis.

Brian J Miller1.   

Abstract

"All-causes discontinuation" refers to discontinuation of treatment for any reason, and adherence to medication is an important component of this measure. Two recent landmark studies suggest that adherence is a major issue in patients with first-episode psychosis (FEP) right from the onset of treatment. In this review, the incidence, reasons for, and clinical outcomes of medication discontinuation in FEP are considered. More than 40% of patients with FEP discontinue medication during the first 9 months of treatment, at which point the chances of relapse increase dramatically. Findings concerning predictors of medication discontinuation in this patient population that have been replicated in more than one study include severity of psychopathology, lack of insight into illness, negative attitudes towards medications, comorbid substance use, and medication side effects. Interventions that have the potential to decrease discontinuation rates in patients with psychotic disorders include orally disintegrating tablets, long-acting injectable drugs, cognitive-behavioral therapy, compliance therapy, family support/intervention, and peer support, although these strategies have largely been unexplored in FEP. In addition to the question of medication discontinuation in the acute treatment of FEP, another important issue is how long patients with FEP should be treated with antipsychotics once they have achieved remission; unfortunately, little evidence is available to guide the decision as to whether medication should be discontinued or maintenance treatment provided in this situation. Studies are therefore needed to identify predictors of patients with remitted FEP who are less likely to relapse when medication is discontinued. Taken together, the findings presented in this article underscore the importance of addressing issues related to medication discontinuation as a means of preventing long-term morbidity and enhancing remission and functional recovery in FEP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832960     DOI: 10.1097/01.pra.0000336756.65308.83

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  11 in total

1.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

2.  Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Authors:  Brian J Miller; Chelsea Bodenheimer; Krystle Crittenden
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

Review 3.  Substance use in clinical high risk for psychosis: a review of the literature.

Authors:  Jean Addington; Nevicia Case; Majid M Saleem; Andrea M Auther; Barbara A Cornblatt; Kristin S Cadenhead
Journal:  Early Interv Psychiatry       Date:  2013-11-14       Impact factor: 2.732

4.  Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study.

Authors:  Rafal A H Yeisen; Jone Bjornestad; Inge Joa; Jan Olav Johannessen; Stein Opjordsmoen
Journal:  BMC Psychiatry       Date:  2017-08-22       Impact factor: 3.630

5.  Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis.

Authors:  Paola Dazzan; Julia M Lappin; Margaret Heslin; Kim Donoghue; Ben Lomas; Uli Reininghaus; Adanna Onyejiaka; Tim Croudace; Peter B Jones; Robin M Murray; Paul Fearon; Gillian A Doody; Craig Morgan
Journal:  Psychol Med       Date:  2019-07-25       Impact factor: 7.723

6.  Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories.

Authors:  Julien Elowe; Julie Ramain; Alessandra Solida; Philippe Conus; Philippe Golay
Journal:  Eur Psychiatry       Date:  2022-08-15       Impact factor: 7.156

7.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15

Review 8.  The nature of relapse in schizophrenia.

Authors:  Robin Emsley; Bonginkosi Chiliza; Laila Asmal; Brian H Harvey
Journal:  BMC Psychiatry       Date:  2013-02-08       Impact factor: 3.630

Review 9.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Authors:  Cristiana Montemagni; Tiziana Frieri; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

Review 10.  Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.

Authors:  Claudio Brasso; Silvio Bellino; Paola Bozzatello; Cristiana Montemagni; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.